Immunicum AB   Report issue

For profit Phase 1 Phase 2
Founded: Gothenburg Sweden (2002)
Status: Acquired by DCPrime BV (2020)

Organization Overview

First Clinical Trial
2012
NCT01525017
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Immunicum AB

Active Ingredients

Drugs in Phase 2 Trials (3)

ilixadencel (3 trials)

pembrolizumab (keytruda) (1 trial)

sunitinib (sutent) (1 trial)

Drugs in Phase 1 Trials (2)

allogeneic dendritic cells (1 trial)

tumor-pulsed dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Gastrointestinal Stromal Tumors (Phase 1)

Papilloma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5